Inmagene Reports Topline Results from Phase 2a Study of
GlobeNewswire - 24 Apr 2025Inmagene Reports Topline Results from Phase 2a Study of ...
phase 2a
Inmagene Reports Topline Results from Phase 2a Study of ...
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
PR Newswire - 15 Apr 2025Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial ...
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Business Wire - 25 Mar 2025Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results ...
Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus
Reuters - 22 Apr 2025Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus ...
Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego
BioSpace - 25 Apr 2025Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego ...
Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success
Stock Titan - 22 Apr 2025Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success ...
A Phase 2a Double-Blind, Placebo-Controlled, Randomized Clinical Trial Evaluating the Efficacy and Safety of NuGel, a Novel Topical GPCR19-Mediated Inflammasome Inhibitor, in Patients with Mild to Moderate Atopic Dermatitis: A Proof-of-Concept Study wi
Frontiers - 21 Apr 2025A Phase 2a Double-Blind, Placebo-Controlled, Randomized Clinical Trial Evaluating the Efficacy and Safety of NuGel, a Novel Topical GPCR19-Mediated Inflammasome Inhibitor, in Patients with Mild to Moderate Atopic Dermatitis: A Proof-of-Concept Study wi ...
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
GlobeNewswire - 08 Apr 2025Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus ...
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
PR Newswire - 10 Mar 2025Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough ...
Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis
Business Wire - 27 Mar 2025Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis ...
Lipella Reports Positive Phase 2a Results from Second
GlobeNewswire - 22 Apr 2025Lipella Reports Positive Phase 2a Results from Second ...
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology
PR Newswire - 12 Mar 2025Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology ...
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Business Wire - 24 Mar 2025Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 ...
Artax Biopharma to present Phase 2a data on Nck modulator
GlobeNewswire - 23 Apr 2025Artax Biopharma to present Phase 2a data on Nck modulator ...
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Business Wire - 10 Mar 2025Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease ...
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
GlobeNewswire - 11 Feb 2025Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus ...
Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain
Business Wire - 04 Feb 2025Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain ...
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
GlobeNewswire - 20 Feb 2025SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL ...
Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
Business Wire - 10 Mar 2025Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease ...